AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30773300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated group (150 mL decaffeinated coffee with additional 200 mg caffeine)
Number of subjects: 201
Study 30773300 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated group (150 mL decaffeinated coffee)
Number of subjects: 201
Study 30773300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated group with CYP1A2 rs762551 CC genotype and daily caffeine consumption ≤90 mg/day
Number of subjects: 201
Study 30773300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated group with CYP1A2 rs762551 AA/CA genotype and daily caffeine consumption ≤90 mg/day
Number of subjects: 201
Study 28511035 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech condition with social threat induction (giving an impromptu speech)
Number of subjects: 91
Study 28511035 — intervention group
Group type: COMPARATOR
Intervention: No-speech condition without social threat induction
Number of subjects: 91
Study 28511035 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech condition with social threat induction
Number of subjects: 91
Study 26209926 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (20mg/kg)
Number of subjects: 16
Study 23819228 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Baihui (GV 20)
Number of subjects: 120
Study 23819228 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120
Study 21519745 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus (30 mg/kg/day)
Number of subjects: 56
Study 18358691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted symptom control intervention
Number of subjects: 214
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of hormone therapy (HT)
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of hormone therapy (HT) in women aged 70-79 years
Number of subjects: 428
Study 16607096 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of hormone therapy (HT)
Number of subjects: 428
Study 16607096 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of hormone therapy (HT) in women aged 60-69 years
Number of subjects: 428
Study 16607096 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of hormone therapy (HT) in women aged 80 years and older
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of hormone therapy (HT) in women aged 70-79 years
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: HT users of less than 11 years
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: HT users of more than 11 years
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐only users
Number of subjects: 428
Study 16607096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen plus progestin users
Number of subjects: 428
Study 14580130 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 36
Study 14580130 — intervention group
Group type: COMPARATOR
Intervention: Random practice
Number of subjects: 36
Study 14580130 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice and Random practice
Number of subjects: 36
Study 10801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangeretin (1 to 100 micromol/L)
Number of subjects: 8
Study 10801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangeretin (50 micromol/L)
Number of subjects: 8
Study 10801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerine juice (200 mL)
Number of subjects: 8
Study 8664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1 (250 mg of standard vitamin C, 200 mg of vitamin E and 6 mg of beta‐carotene three times a day)
Number of subjects: 43
Study 8664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 (150 mg of standard vitamin C, 500 mg of slow release vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene once a day)
Number of subjects: 43
Study 8664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 43
Study 8664811 — intervention group
Group type: COMPARATOR
Intervention: H. pylori isolates
Number of subjects: 43
Study 1477566 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 70
Study 1477566 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 70
Study 6703731 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Goeckerman therapy (hospitalized throughout average 20.8 days)
Number of subjects: 162
Study 6703731 — intervention group
Group type: COMPARATOR
Intervention: Modified Goeckerman therapy (hospitalized for 14 days, then transferred to ambulatory care for remainder of average 20.8 days)
Number of subjects: 162
Study 6703731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 31877766 — intervention group
Group type: COMPARATOR
Intervention: Gal3C-S-OPN/full-length-OPN levels in stone forming urolithiasis patients
Number of subjects: 110
Study 31877766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal3C-S-OPN/full-length-OPN levels after ureteroscopic lithotripsy (URS)
Number of subjects: 110
Study 29429764 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 424
Study 27413441 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation intervention
Number of subjects: 45
Study 27413441 — intervention group
Group type: COMPARATOR
Intervention: No-affirmation condition (Control)
Number of subjects: 45
Study 25121620 — intervention group
Group type: EXPERIMENTAL
Intervention: MORE Energy mobile application with tailored advice and a website with background information
Number of subjects: 502
Study 25121620 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard information about fatigue
Number of subjects: 502
Study 21246373 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate+placebo
Number of subjects: 40
Study 21246373 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate+cyclosporine A
Number of subjects: 40
Study 21246373 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 40
Study 20672352 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE followed by RFA on the same day
Number of subjects: 37
Study 20672352 — intervention group
Group type: COMPARATOR
Intervention: RFA alone
Number of subjects: 37
Study 17407493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 9
Study 17407493 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 9
Study 15887427 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg HPV 16 L1 VLP vaccine
Number of subjects: 480
Study 15887427 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg HPV 16 L1 VLP vaccine
Number of subjects: 480
Study 15887427 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg HPV 16 L1 VLP vaccine
Number of subjects: 480
Study 15887427 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg HPV 16 L1 VLP vaccine
Number of subjects: 480
Study 15887427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 11350534 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic allopurinol (Normon)
Number of subjects: 24
Study 11350534 — intervention group
Group type: COMPARATOR
Intervention: Zyloric tablets
Number of subjects: 24
Study 9129372 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term home-based intervention with written material and video feedback; 4 intervention sessions.
Number of subjects: 1
Study 9129372 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Attachment Interview administered after intervention.
Number of subjects: 1
Study 7893586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg twice daily
Number of subjects: 24
Study 7893586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg twice daily
Number of subjects: 24
Study 7893586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2853497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified non‐medicamentous basic therapy (fat‐modified diet and endurance training)
Number of subjects: 1139
Study 2853497 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 1139
Study 2853497 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibric acid (1.6 g)
Number of subjects: 1139
Study 31214935 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist approach (PCP delivered brief intervention for substance misuse)
Number of subjects: 9639
Study 31214935 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist approach (BHCs delivered brief interventions)
Number of subjects: 9639
Study 31214935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (Generalist and Specialist)
Number of subjects: 9639
Study 29276166 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated oxytocin titration (AOT) - initial dose 4 mU/min with increments of 4 mU/min
Number of subjects: 79
Study 29276166 — intervention group
Group type: COMPARATOR
Intervention: Standard gradual oxytocin titration (GOT) - initial dose 2 mU/min with increments of 2 mU/min
Number of subjects: 79
Study 27727383 — intervention group
Group type: COMPARATOR
Intervention: Surgery (n=309)
Number of subjects: 620
Study 27727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting (n=311)
Number of subjects: 620
Study 27727383 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 620
Study 27727383 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting
Number of subjects: 620
Study 25636934 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc therapy
Number of subjects: 13
Study 23496916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (weight loss and hypertension management trial)
Number of subjects: 365
Study 23496916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 365
Study 23496916 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies (financial incentives, contact between assessment visits, building relationships with health center staff)
Number of subjects: 365
Study 23496916 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (passive approval by PCPs, part-time staff, outsourcing calls)
Number of subjects: 365
Study 20801085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A (3.5-4.0 mg/kg per day)
Number of subjects: 153
Study 20801085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A with intermittent prednisone (0.75 mg/kg, alternating 10 days on with 10 days off)
Number of subjects: 153
Study 20801085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 20801085 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intermittent prednisone
Number of subjects: 153
Study 20801085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin A
Number of subjects: 153
Study 19140649 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged lifestyle program (team-based competition in ill-defined problem solving)
Number of subjects: 0
Study 19140649 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16600770 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 120
Study 16600770 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 120
Study 12742287 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 0
Study 12742287 — intervention group
Group type: COMPARATOR
Intervention: Balloon percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 10507567 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine tartrate 0.2%
Number of subjects: 60
Study 10507567 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 60
Study 8942375 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching the fellow eye in infancy (intervention for unilateral congenital cataract)
Number of subjects: 12
Study 8942375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweep VEP method (used for estimating acuity)
Number of subjects: 12
Study 8942375 — intervention group
Group type: COMPARATOR
Intervention: Binocular controls (control group)
Number of subjects: 12
Study 8942375 — intervention group
Group type: COMPARATOR
Intervention: Severe untreated uniocular visual impairment (comparison group)
Number of subjects: 12
Study 1902417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin or Adriamycin administered endovesically
Number of subjects: 276
Study 1902417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoprostatourethrectomy
Number of subjects: 276
Study 7078276 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medical record summary system
Number of subjects: 479
Study 7078276 — intervention group
Group type: COMPARATOR
Intervention: Manual record
Number of subjects: 479
Study 29174738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg (AOM 400)
Number of subjects: 0
Study 29174738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26793971 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation of essential amino acids (EAAs) for 12 weeks
Number of subjects: 0
Study 26793971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24323795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 17951
Study 24323795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 17951
Study 24323795 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 17951
Study 24323795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg and 110 mg
Number of subjects: 17951
Study 22509905 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg nebulized ipratropium bromide
Number of subjects: 39
Study 22509905 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 39
Study 20060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cholecalciferol 800 IU + calcium carbonate 1000 mg
Number of subjects: 3139
Study 20060665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation or placebo)
Number of subjects: 3139
Study 18776199 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC transplantation
Number of subjects: 50
Study 15668775 — intervention group
Group type: EXPERIMENTAL
Intervention: Real insoles
Number of subjects: 58
Study 15668775 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 58
Study 12208727 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft transplantation (group A)
Number of subjects: 79
Study 12208727 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal-conjunctival autograft transplantation (group B)
Number of subjects: 79
Study 10086969 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine at a dosage of 75 mg/d
Number of subjects: 126
Study 10086969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 8650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with borderline essential hypertension
Number of subjects: 21
Study 8650034 — intervention group
Group type: EXPERIMENTAL
Intervention: High renin patients
Number of subjects: 21
Study 8650034 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal renin patients
Number of subjects: 21
Study 8650034 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 21
Study 2402123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane (Cu) dialysis membranes
Number of subjects: 8
Study 2402123 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (PAN) dialysis membranes
Number of subjects: 8
Study 6445050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 20
Study 6445050 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 6445050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Saline
Number of subjects: 20
Study 6132936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (18 mg/day)
Number of subjects: 48
Study 6132936 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg/day)
Number of subjects: 48
Study 6132936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6132936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 48
Study 30897239 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk garments
Number of subjects: 0
Study 30897239 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29973312 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages selected by participants (TM-PBS)
Number of subjects: 48
Study 29973312 — intervention group
Group type: COMPARATOR
Intervention: Text messages selected by investigators (TM-PBS)
Number of subjects: 48
Study 29973312 — intervention group
Group type: COMPARATOR
Intervention: Text messages selected at random (TM-PBS)
Number of subjects: 48
Study 26658264 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 541
Study 26658264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 24780955 — intervention group
Group type: EXPERIMENTAL
Intervention: rTSMS (repetitive trans-spinal magnetic stimulation); a train of 40 stimuli
Number of subjects: 37
Study 24780955 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 37
Study 24780955 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 37
Study 23110368 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg NGX426
Number of subjects: 18
Study 23110368 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg NGX426
Number of subjects: 18
Study 23110368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20193083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi program plus standard care
Number of subjects: 86
Study 20193083 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 86
Study 18829801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in the upper quartile at baseline
Number of subjects: 350
Study 18829801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol values >90th percentile
Number of subjects: 350
Study 18829801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol values <10th percentile or >90th percentile
Number of subjects: 350
Study 18829801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cortisol values at baseline or day 5 to 7
Number of subjects: 350
Study 18829801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cortisol values
Number of subjects: 350
Study 18829801 — intervention group
Group type: COMPARATOR
Intervention: Cortisol concentrations
Number of subjects: 350
Study 15778883 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.62 g/kg alcohol (A)
Number of subjects: 36
Study 15778883 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward for good performance during rising BACs (AR)
Number of subjects: 36
Study 15778883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 36
Study 15778883 — intervention group
Group type: COMPARATOR
Intervention: Reward for good performance during placebo (PR)
Number of subjects: 36
Study 15778883 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining BACs (73 mg/100 ml)
Number of subjects: 36
Study 15778883 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining BACs (64 mg/100 ml)
Number of subjects: 36
Study 11815311 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine rich in ALA (15% ALA; n = 114)
Number of subjects: 282
Study 11815311 — intervention group
Group type: COMPARATOR
Intervention: Margarine rich in LA (0.3% ALA; n = 168)
Number of subjects: 282
Study 11815311 — intervention group
Group type: EXPERIMENTAL
Intervention: Group nutritional education (n = 110; 50% ALA)
Number of subjects: 282
Study 11815311 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 172; 34% ALA)
Number of subjects: 282
Study 10395399 — intervention group
Group type: COMPARATOR
Intervention: Group tube (direct injection into the upper end of the endotracheal tube)
Number of subjects: 35
Study 10395399 — intervention group
Group type: COMPARATOR
Intervention: Group EDGAR (endotracheal tube with an injection channel within the wall of the tube)
Number of subjects: 35
Study 10395399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group suction catheter (suction catheter placed into the bronchial system)
Number of subjects: 35
Study 10395399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group venous catheter (flexible venous catheter placed into the bronchial system)
Number of subjects: 35
Study 10395399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group suction tube (interruption of chest compressions and ventilation)
Number of subjects: 35
Study 10395399 — intervention group
Group type: EXPERIMENTAL
Intervention: Group catheter (interruption of chest compressions and ventilation)
Number of subjects: 35
Study 10395399 — intervention group
Group type: COMPARATOR
Intervention: Group tube (interruption of chest compressions and ventilation)
Number of subjects: 35
Study 7537116 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 480 micrograms subcutaneously
Number of subjects: 21
Study 7537116 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 2386449 — intervention group
Group type: EXPERIMENTAL
Intervention: +3 Gz
Number of subjects: 5
Study 2386449 — intervention group
Group type: EXPERIMENTAL
Intervention: Facing forward and facing backward conditions
Number of subjects: 5
Study 7324741 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with 0.5% bupivacaine and epinephrine (5 micrograms/ml)
Number of subjects: 30
Study 7324741 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with nitrous oxide/oxygen, fentanyl, and pancuronium bromide
Number of subjects: 30
Study 31199090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg voxelotor
Number of subjects: 274